BlueZenith
Greenlighter
I'm new here; if this is in the wrong place or has come up before, I apologise.
Given these facts:
Van Oekelen, D., Luyten., W.H.M.L., and Leysen, J.E. (2003) 5-HT2A and 5-HT2C receptors and their atypical regulation properties, Life Sciences, Vol. 72 Issue 22, 18 April 2003, pp2429-2449
Moreno, F.A., Wiegand, C.B., Taitano, E.K. and Delgado, P.L. (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder, Journal of Clinical Psychiatry, Vol. 67 Issue 11, November 2006, pp1735-1740
Given these facts:
- 5-HT2A and 2C receptor activation is associated with psychotic symptoms;
- Blockade of these receptors using antagonists (e.g., atypical anti-psychotics) relieves the symptoms of psychosis;
- Said receptors appear to be down-regulated by almost any type of ligand, including both agonists (e.g., psychedelic drugs) and, paradoxically, antagonists (van Oekelen, Luyten & Leysen, 2003);
- Treatment with psychedelic drugs can produce psychotherapeutic effects at sub-psychedelic dosages and without significant side effects (Moreno, Wiegand, Taitano & Delgado, 2006), conceivably through said receptor down-regulation.
Van Oekelen, D., Luyten., W.H.M.L., and Leysen, J.E. (2003) 5-HT2A and 5-HT2C receptors and their atypical regulation properties, Life Sciences, Vol. 72 Issue 22, 18 April 2003, pp2429-2449
Moreno, F.A., Wiegand, C.B., Taitano, E.K. and Delgado, P.L. (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder, Journal of Clinical Psychiatry, Vol. 67 Issue 11, November 2006, pp1735-1740
